Bangladesh Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Bangladesh

2. Grant number(s): 1418-BGD-25b-X / 1418-BGD-25b-Y / 17-BGD-25e-X / 14-BGD-08h-Y

3. Date of Decision Letter: 19 October 2017 (This Decision Letter replaces the previous Decision Letter for IPV dated 19 April 2017)

4. Date of the Partnership Framework Agreement: 24 June 2013

5. Programme title: NVS, IPV routine and catch-up

6. Vaccine type: Inactivated Polio Vaccine (IPV)

7. Requested product presentation and formulation of vaccine: Fractional use of Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID


9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement)

   Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi’s review and approval processes.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine Programme</td>
<td>9,660,310</td>
<td>2,425,500</td>
<td>12,085,810</td>
</tr>
<tr>
<td>Programme (US$)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Catch-up vaccination</td>
<td>0</td>
<td>1,274,500</td>
<td>1,274,500</td>
</tr>
<tr>
<td>vaccination (US$)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Budget (US$)</td>
<td>9,660,310</td>
<td>3,700,000</td>
<td>13,360,310</td>
</tr>
</tbody>
</table>

10. Vaccine introduction grant / Product switch grant: US$2,498,000 was disbursed on 14 August 2014. The use of residual funds from the IPV VIG to support the switch to fractional dose IPV was most recently approved on 20 September 2017.

---

1 Please refer to section 18 for additional information on IPV presentation.
2 This is the entire duration of the Programme.
3 This is the total amount endorsed by Gavi for 2015 to 2018.
4 This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.
11. Indicative Annual Amounts:
(subject to the terms of the Partnership Framework Agreement)⁵

<table>
<thead>
<tr>
<th>Number of vaccine doses to be purchased with Gavi funds</th>
<th>2014-2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV Routine Programme (doses)</td>
<td></td>
<td>1,240,700</td>
</tr>
<tr>
<td>IPV Catch-up vaccination (doses)</td>
<td></td>
<td>658,200</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$ 9,660,310</td>
<td>US$ 3,700,000</td>
</tr>
</tbody>
</table>

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not applicable

14. Co-financing obligations: Not applicable
   Gavi’s usual co-financing requirements do not apply to IPV. However, Bangladesh is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for catch-up campaigns: Not applicable

16. Additional reporting requirements:

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td>
<td>May</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

17. Financial clarifications: Country shall provide the following clarifications to Gavi*:
   Not applicable

   *Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements

⁵ This is the amount that Gavi has approved.
18. Other conditions:
Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Bangladesh envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Bangladesh.

Signed by,
On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
19 October 2017